# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elvis Presley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML003-SYN
- Date: 2026-07-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Coleman Ashby-Nakagawa, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

One-week review, seen the same day by addiction medicine. **S**

## History of present illness

Mr. Presley returns one week after intake and is seen by Dr. Eberhardt-Mensah of addiction medicine on the same day. He has taken only the medicines this clinic prescribed, from one pharmacy, and brought the remaining tablets. As agreed, he took his last hydromorphone about 18 hours ago and his last oxycodone about 20 hours ago so that buprenorphine could be started today; he has yawning, a runny nose, aching legs, gooseflesh and loose stools. He took his usual diazepam and alprazolam last night. His in-laboratory sleep study three days ago showed moderate obstructive sleep apnea. His home blood pressure readings over six days, after stopping phentermine, averaged 146/94. His bowels opened twice this week on polyethylene glycol and senna. He has kept his firearms locked and the naloxone in the house. He says he is ready to start treatment before his engagement. **S**

| Element | Detail |
|---|---|
| Last full-agonist opioid | Hydromorphone 18 hours ago; oxycodone 20 hours ago |
| Withdrawal | Yawning, rhinorrhea, aching, gooseflesh, loose stools; COWS 12 (moderate) |
| Sleep study | Apnea-hypopnea index 26; central apnea index 4; nadir 80% |
| Home blood pressure | Average 146/94 over six days |
| Bowels | Twice this week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Aching and chills from withdrawal |
| Gastrointestinal | Positive | Loose stools today; mild cramps |
| Eyes | Positive | Watery eyes; no pain or halos |
| Psychiatric | Positive | Anxious about withdrawal; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist **S**
- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag **S**
- Polyethylene glycol 3350, 17 g powder in a glass of water once daily **S**
- Senna 8.6 mg oral tablet, two tablets at bedtime **S**
- Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only **S**
- Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stable **S**
- Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 146/94 mmHg; pulse 102 bpm; respirations 18/min; temperature 37 °C; oxygen saturation 96% on room air; weight 108.6 kg; BMI 32.4 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Restless, yawning; blood pressure 146/94, pulse 102, temperature 37.0 °C |
| Eyes | Pupils 5 mm and reactive; lacrimation |
| Skin | Piloerection; sweating; no injection marks |
| Neurological | Mild tremor of the outstretched hands; alert and oriented |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Opioid use disorder, severe** (F11.20). Dr. Eberhardt-Mensah confirms opioid use disorder, severe, with seven DSM-5-TR criteria: more taken than intended, unsuccessful efforts to cut down, much time spent getting prescriptions from several prescribers, craving, continued use despite sleepiness and constipation, tolerance and withdrawal (counted because the opioids were not taken as prescribed). Buprenorphine is the treatment of choice; taking a benzodiazepine is not a reason to withhold it, but the combination calls for naloxone, a single prescriber and close follow-up. COWS 12 today, so buprenorphine was started in the office: 4 mg, then 4 mg after an hour, with withdrawal settling. **S**
   - Buprenorphine with naloxone 16 mg tomorrow and daily after that.
   - Full-agonist opioids stopped; remaining tablets taken back.
   - Weekly phone or video contact for the first month; counseling started.
   - Naloxone continued.
2. **Benzodiazepine use disorder, moderate** (F13.20). Five criteria met; daily diazepam and alprazolam for years mean a risk of seizures if stopped quickly. The two benzodiazepines are combined into diazepam alone, a long-acting drug, at 40 mg a day, a cautious equivalent of his combined doses, and held there until buprenorphine is stable. **S**
   - Diazepam 10 mg four times daily; alprazolam stopped.
   - Taper by about 5 to 10% every two to four weeks once buprenorphine is stable, starting at the next visit if he is ready.
   - CBT for anxiety and insomnia.
3. **Obstructive sleep apnea, moderate** (G47.33). Moderate obstructive sleep apnea, with a small central component that opioids and benzodiazepines can worsen; CPAP at 11 cm H2O controlled events in the titration. **S**
   - CPAP nightly, with a travel machine.
   - No sedative added for sleep.
4. **Hypertension, stage 2** (I10). A home average of 146/94 a week after stopping phentermine confirms stage 2 hypertension, more than 10 mmHg above the diastolic target, so two first-line drugs are started together. Today's office reading is raised further by withdrawal. **S**
   - Amlodipine 5 mg with valsartan 160 mg once daily.
   - Potassium and creatinine in two to four weeks.
   - Home readings twice daily for a week before the next visit.
5. **Opioid-induced constipation** (K59.03). Meets Rome IV criteria for opioid-induced constipation; buprenorphine usually constipates less than full agonists. **S**
   - Continue polyethylene glycol and senna.
6. **Fatigue, weight gain, constipation, sleepiness and high blood pressure** (R53.83). Explained by the diagnoses made today; this presenting problem is closed. **S**
   - Followed under each diagnosis.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, withdrawal symptoms, cravings and other opioid use | Every visit; weekly contact in the first month | Completed today | COWS 12 before the first dose; 8 mg given in the office; 16 mg a day from tomorrow |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's seven-day prescriptions since intake; the earlier prescribers notified that this clinic now prescribes |
| Laboratory | Urine drug test, including buprenorphine metabolite and fentanyl | At the start of treatment, then about monthly while doses are changing | Completed today | Point-of-care test today: hydromorphone, oxycodone and benzodiazepines present; fentanyl and other drugs absent (narrative) |
| Medication safety | Naloxone on hand and people taught to use it | Every visit | Completed today | Two-pack at home and one in the tour bag; two friends trained |
| Medication safety | Diazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper pace | Every two to four weeks during the taper | Completed today | Diazepam 30 mg and alprazolam 3 mg a day combined into diazepam 40 mg a day; no taper step during the buprenorphine start |
| Survey | Suicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; firearms locked; medicines in a locked box; 988 in his phone |
| Survey | Mood (PHQ-9) and anxiety (GAD-7) | At baseline, four to six weeks after a change in treatment, then at each review | Up to date | PHQ-9 8 and GAD-7 9 at intake; repeat at the next visit |
| Examination | Office and home blood pressure (target below 130/80) | Every visit | Completed today | Office 146/94 in withdrawal; home average 146/94; treatment started |
| Imaging | Electrocardiogram at diagnosis of hypertension | At diagnosis | Up to date | Normal at intake, QTc 436 ms |
| Laboratory | Potassium and creatinine after starting an angiotensin receptor blocker | Two to four weeks after starting, then every six months | Due | Valsartan started today; check at the next visit |
| Examination | Weight and BMI | Every visit | Completed today | 108.6 kg, BMI 32.4 |
| Survey | CPAP adherence (device data) and sleepiness (Epworth, recorded as narrative) | Within the first 30 to 90 days, then at each review | Due | Polysomnogram three days ago; CPAP starts this week |
| Self-management | Bowel frequency, straining and alarm features | Every visit | Completed today | Twice this week; no blood, weight loss or vomiting |
| Examination | Glaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-up | Every visit; ophthalmology every three to six months while recently controlled | Completed today | Latanoprost nightly; phentermine and the nonprescription diphenhydramine sleep aid stopped; no eye pain or halos; ophthalmology visit in September |
| Referral | Addiction medicine consultation | At diagnosis | Completed today | Seen by Dr. Eberhardt-Mensah today |
| Self-management | Touring plan: one named pharmacy, video visits while away, CPAP and naloxone in the tour bag, no dose change in the week before an engagement | Before each engagement or tour | Up to date | Las Vegas engagement in five weeks; plan to be written at the next visit |

## Goal progress

- Stop full-agonist opioids and stabilize on buprenorphine without significant withdrawal. In progress; target 2026-08-07. **S**
- One prescriber and one pharmacy for all controlled medicines. In progress; target 2026-09-23. **S**
- Lower the diazepam dose slowly, 5 to 10% every two to four weeks, toward stopping. In progress; target 2026-10-28. **S**
- Home blood pressure below 130/80. In progress; target 2026-08-07. **S**
- Lose 5% or more of body weight. In progress; target 2026-10-28. **S**
- CPAP on at least 70% of nights for four hours or more, with less daytime sleepiness. In progress; target 2026-10-28. **S**
- A bowel movement at least every two days without straining. In progress; target 2026-08-07. **S**

## Medication changes

- Stopped: Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultation **S**
- Stopped: Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultation **S**
- Stopped: Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a time **S**
- Stopped: Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a time **S**
- Started: Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only **S**
- Started: Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stable **S**
- Started: Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily **S**

## Guideline basis

- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recomm Rep 2022;71(3):1-95)
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (J Addict Med 2020;14(2S Suppl 1):1-91)
- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (2019), American Academy of Sleep Medicine (J Clin Sleep Med 2019;15(2):335-343)
- American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation (2019), American Gastroenterological Association (Gastroenterology 2019;156(1):218-226)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Phone check tomorrow and weekly contact. Three-week review. Call or use naloxone and 911 for heavy sedation or slow breathing. **S**
- Next scheduled visit 2026-08-07: three-week review on buprenorphine: withdrawal and cravings, the first benzodiazepine taper step, blood pressure treatment, CPAP, constipation and weight, and planning for a Las Vegas engagement. **S**
